scholarly journals Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?

PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0218556 ◽  
Author(s):  
Kayla Stankevitz ◽  
Katie Schwartz ◽  
Theresa Hoke ◽  
Yixuan Li ◽  
Michele Lanham ◽  
...  
Keyword(s):  
At Risk ◽  
Clinical Trials ◽  
Sub Saharan Africa ◽  
Sub Saharan

scholarly journals Contraceptive dynamics during COVID-19 in sub-Saharan Africa: longitudinal evidence from Burkina Faso and Kenya

2021 ◽  
pp. bmjsrh-2020-200944
Author(s):  
Celia Karp ◽  
Shannon N Wood ◽  
Georges Guiella ◽  
Peter Gichangi ◽  
Suzanne O Bell ◽  
...  
Keyword(s):  
At Risk ◽  
Burkina Faso ◽  
Unintended Pregnancy ◽  
Sexual And Reproductive Health ◽  
Universal Access ◽  
Sociodemographic Factors ◽  
Sub Saharan Africa ◽  
Contraceptive Services ◽  
Logistic Regressions ◽  
Sub Saharan

IntroductionEvidence from health emergencies suggests COVID-19 will disrupt women’s sexual and reproductive health (SRH). In sub-Saharan Africa, which experiences the highest rates of unintended pregnancy and unsafe abortion globally, COVID-19 is projected to slow recent progress toward universal access to contraceptive services.MethodsWe used longitudinal data collected from women at risk of unintended pregnancy in Burkina Faso (n=1186) and Kenya (n=2784) before (November 2019–February 2020) and during (May–July 2020) COVID-19 to quantify contraceptive dynamics during COVID-19; examine sociodemographic factors and COVID-19 experiences related to contraceptive dynamics; and assess COVID-19-related reasons for contraceptive non-use. Bivariate and multivariate logistic regressions were used to examine correlates of contraceptive dynamics amid COVID-19.ResultsMost women did not change their contraceptive status during COVID-19 (68.6% in Burkina Faso and 81.6% in Kenya) and those who did were more likely to adopt a method (25.4% and 13.1%, respectively) than to discontinue (6.0% and 5.3%, respectively). Most women who switched contraceptives were using methods as or more effective than their pre-pandemic contraception. Economic instability related to COVID-19 was associated with increased contraceptive protection in Burkina Faso but not in Kenya. Altogether, 14.4% of non-contraceptive users in Kenya and 3.8% in Burkina Faso identified COVID-19-related reasons for non-use.ConclusionsThe vast majority of women at risk of unintended pregnancy did not change their contraceptive status during COVID-19, and more women adopted than discontinued methods. A minority of women reported COVID-19-related reasons for non-use, underscoring the importance of expanding safe modes of service delivery during health crises.

scholarly journals Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Neema Toto ◽  
Elaine Douglas ◽  
Markus Gmeiner ◽  
Lynn K. Barrett ◽  
Robert Lindblad ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Lessons Learned ◽  
Sub Saharan Africa ◽  
Sub Saharan

scholarly journals Considerations for stakeholder engagement and COVID ‐19 related clinical trials’ conduct in sub‐Saharan Africa

2020 ◽  
Author(s):  
Morenike Oluwatoyin Folayan ◽  
Brandon Brown ◽  
Bridget Haire ◽  
Chinedum Peace Babalola ◽  
Nicaise Ndembi
Keyword(s):  
Clinical Trials ◽  
Stakeholder Engagement ◽  
Sub Saharan Africa ◽  
Sub Saharan

Clinical Trials in Sub-Saharan Africa and Established Standards of Care

JAMA ◽  
2004 ◽  
Vol 292 (2) ◽  
pp. 237 ◽  
Author(s):  
David M. Kent ◽  
D. Mkaya Mwamburi ◽  
Michael L. Bennish ◽  
Bruce Kupelnick ◽  
John P. A. Ioannidis
Keyword(s):  
Clinical Trials ◽  
Sub Saharan Africa ◽  
Standards Of Care ◽  
Sub Saharan

scholarly journals "You can save time if…"—A qualitative study on internal factors slowing down clinical trials in Sub-Saharan Africa

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0173796 ◽  
Author(s):  
Nerina Vischer ◽  
Constanze Pfeiffer ◽  
Manuela Limacher ◽  
Christian Burri
Keyword(s):  
Clinical Trials ◽  
Qualitative Study ◽  
Sub Saharan Africa ◽  
Internal Factors ◽  
Slowing Down ◽  
Sub Saharan

Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa

2013 ◽  
Vol 10 (10) ◽  
pp. 599-604 ◽  
Author(s):  
Trijn Israëls ◽  
Joyce Kambugu ◽  
Francine Kouya ◽  
Nader Kim El-Mallawany ◽  
Peter B. Hesseling ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Childhood Cancer ◽  
Cancer Care ◽  
Sub Saharan Africa ◽  
Sub Saharan

scholarly journals Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials

2021 ◽  
pp. 1358-1363
Author(s):  
Abiola Ibraheem ◽  
Colin Pillai ◽  
Ifeoma Okoye ◽  
J. Joshua Smith ◽  
Diane Reidy-Lagunes ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Sub Saharan Africa ◽  
Cancer Clinical Trials ◽  
Future Directions ◽  
Secondary Purpose ◽  
Health Care Burden ◽  
Sub Saharan ◽  
Cancer Disparity ◽  
And Training

Cancer is now a formidable health care burden in sub-Saharan Africa (SSA) due to lifestyle westernization and longer life expectancy. The exponential increase in cancer incidence coupled with high mortality rate is not comparable with that seen in westernized countries. To address global cancer disparity, globalization of cancer clinical trials to involve sub-Saharan Africa can serve as a platform where innovative targeted therapies can be made available to patients in the environ. In the 2019 African Organization for Research and Training in Cancer (AORTIC) conference held at Maputo, Mozambique, a group of clinical trialists spanning across multiple continents highlighted the opportunities in Africa for the conduct of cancer clinical trials. The secondary purpose of the meeting was to address the belief that Africa was incapable of conducting interventional cancer trials but showed the in-continent strengths, such as available capacities, trained local clinical trialists with clinical trial experiences, clinical trial consortia, local capabilities, mapping out logistics, ethical consideration, political will, real-time benefits of clinical trials to clinical practice, and future directions for trials.

Sign in / Sign up

Export Citation Format

Share Document